NeuroSigma is a neurotechnology company developing non-invasive neuromodulation therapies based on external trigeminal nerve stimulation. The company focuses on delivering targeted electrical stimulation during sleep to modulate neural circuits involved in attention and cognitive regulation.

Its core product, the Monarch® eTNS System, delivers low-level electrical stimulation to branches of the trigeminal nerve via a small adhesive electrode placed on the forehead. The system is designed for home use and is programmed to deliver therapy overnight with minimal disruption to daily activities.

NeuroSigma’s technology is intended for clinical use in pediatric populations, particularly for the treatment of attention-deficit/hyperactivity disorder. The company positions its platform as a clinically validated neuromodulation therapy that offers a non-pharmacological alternative for managing neurological and neurodevelopmental conditions.